FEMY

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys (FEMY - Research Report), with a price target of $5.00. The company's shares opened today at $1.06.According to TipRanks, McCarthy is an analyst with an average return of -37.2% and a 15.33% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Lineage Cell Therapeutics.Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $7.33.See today’s best-performing stocks on TipRanks >>Based on Femasys' latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $347.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-femasys-femy-3?utm_source=advfn.com&utm_medium=referral